Efficacy for its newest product, Prostreatm has been demonstrated by NucleoBio Inc. in its attempt to develop a drug that can efficiently treat aggressive prostate cancer.
Preventing the growth and spread of the most aggressive form of prostate cancer – metastatic castration-resistant prostate cancer, is done better by Prostreat compared to commercially available medications, claimed the company. New, advanced technology for inhibiting the growth and spread of aggressive prostate cancer is made use of by Prostreat.
Prostreat was developed in his laboratory at Hunter College of The City University of New York by NucleoBio co-founder Olorunseun Ogunwobi.
Some of the other widely used medications for advanced stage prostrate cancer such as Enzalutamide, Abiraterone and Apalutamide were used for comparison and measurement of the effectiveness of Prostreat. Results have demonstrated the enhanced ability of Prostreat in significantly inhibiting growth and spread of aggressive prostate cancer which typically expresses the ARV7 mutant protein which can is known to lead to drug resistance.
On the other hand, insignificant therapeutic effect on the drug resistant form of castration-resistant prostate cancer was found for the commercially available therapeutics that were considered in the studies.”We unveiled ineffectiveness in current therapies for this type of cancer and identified voids,” said NucleoBio co-founder and CEO, Charles Oyesile. “With the support of CUNY, we leveraged the latest advances in cancer research to create Prostreat, which outperformed current therapeutics in side-by-side laboratory tests.”
The NucleoBio team ended its preliminary product testing of Prostreat done on animals in New York in March 2018. The team is completely dedicated towards the study and testing of new treatment methods for cancer since the last decade or so.
Prostreat was created from synthetic analogs of microRNAs by Dr. Ogunwobi, who led the research. “We created synthetic analogs of specific microRNAs that we identified from our research, and have demonstrated their superior anti-tumor and anti-metastatic properties in aggressive metastatic castration-resistant prostate cancer, as compared to commercially utilized drugs,” Dr. Ogunwobi said. “This type of technology is relatively new, and to my knowledge, there is no other synthetic microRNA analog that is used in the treatment of prostate cancer.”
The most effective medications available curuently currently are Enzalutamide, Abiraterone and Apalutamide which are considered to be second-generation drugs. There are significant concerns among some sections of patient populations about the unintended side effects and drug resistance of these drugs even though some patient population found this generation of drugs to be beneficial.
The results of the study the shows the ability of Prostreat to prevent the proliferation, migration, growth, and metastasis of prostate tumors would be published in a medical journal later in 2018. The outcome would also be presented at the European Association for Cancer Research in Amsterdam, by Dr. Ogunwobi.
(Adapted from PRNewswire.com)